Grandi asked
What Is Striverdi Respimat?
Answer
Strivendi Respimat (olodaterol) is known as a long-acting beta-agonist maintenance inhaler for COPD. There are many different drugs in this class including Serevent and Foradil. What makes Striverdi different is that it is only dosed once daily compared to twice daily for the other two drugs that I mentioned. I will break down some key points in regards to the drug below:
What Is Striverdi Used For?
It is FDA-approved for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
How Does Striverdi Work?
Striverdi is a long-acting beta2-adrenergic agonist, otherwise known as a LABA. Beta-2 receptors are present in large numbers in the lungs and are located on bronchiolar smooth muscle. Stimulation of beta-2 receptors (by drugs such as Striverdi) in the lung causes relaxation of bronchial smooth muscle, which produces bronchodilation and a resultant increase in bronchial airflow making it easier to breathe.
How Much Does Striverdi Cost?
As with all drugs, it depends on your insurance and whether or not it is a covered medication. If you were paying the cash price out of pocket, it costs about $155 per month. This is actually less compared to other long acting beta 2 agonists which cost about $200 out of pocket
How Many Doses Come With The Inhaler?
The inhaler has 60 puffs (equal to 30 doses of medicine) since each dose included two puffs. There is a dose counter on the medicine.
Are There Any Side Effects?
Striverdi can produce clinically significant cardiovascular effects in some patients, as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of Striverdi at recommended doses, if they occur, the drug may need to be discontinued.
In addition, the following occurred during clinical trials
Upper respiratory tract infection (8.2% vs 7.5% placebo)
Bronchitis (4.7% vs 3.6% placebo)
Urinary tract infection (2.5% vs 1% placebo)
Cough (4.2% vs 4% placebo)
Back pain (3.5% vs 2.7% placebo)
